The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug ...

In February, a small biotech company reached a breakthrough with the FDA, agreeing to a clinical trial plan. The problem: The ...

U.S. pharmaceutical giant Eli Lilly will give Hong Kong-listed Insilico $115 million upfront to bring some of its ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the second quarter: Abivax: ...

US drugmaker Eli Lilly has signed a $2bn deal with a Hong Kong-listed company that uses AI for drug discovery, highlighting ...

We explore what allosteric modulators are, their benefits and drawbacks, and which candidates are currently advancing through ...

The upcoming FDA decision for Replimune’s advanced melanoma drug could be a litmus test for the agency's future regulatory ...

Lilly licenses Insilico's AI drug discovery platform in a deal worth up to $2.75B, signaling a shift in how novel ...

ORLANDO, FL / ACCESS Newswire / April 2, 2026 / RedChip Companies, an industry leader in investor relations, media, and ...

Jyong Biotech Ltd. (Nasdaq: MENS) (the 'Company” or 'Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics ...